Vicore Pharma Holding AB (publ) (VCRE)
| Market Cap | 291.21M +12.1% |
| Revenue (ttm) | 383,476 -55.0% |
| Net Income | -52.54M |
| EPS | -1.93 |
| Shares Out | 282.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,244 |
| Open | 10.37 |
| Previous Close | 10.01 |
| Day's Range | 10.37 - 10.37 |
| 52-Week Range | 7.88 - 17.80 |
| Beta | 0.10 |
| Analysts | Strong Buy |
| Price Target | 30.08 (+189.23%) |
| Earnings Date | Nov 5, 2026 |
About VCRE
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III cl... [Read more]
Financial Performance
In 2025, Vicore Pharma Holding AB's revenue was 3.82 million, a decrease of -96.51% compared to the previous year's 109.35 million. Losses were -477.47 million, 183.1% more than in 2024.
Financial numbers in SEK Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for VCRE stock is "Strong Buy." The 12-month stock price target is $30.08, which is an increase of 189.23% from the latest price.
News
Vicore Pharma Holding AB Quarterly report: Q3 2026
Vicore Pharma Holding AB has published its Q3 2026 quarterly earnings report on November 5, 2026.
Vicore Pharma initiated with a Buy at Chardan
Chardan initiated coverage of Vicore Pharma (VCRE) with a Buy rating and $15 price target Buloxibutid, a first-in-class oral AT2 receptor agonist, produced some of the most striking lung-function data...
Vicore Pharma Holding AB Slides: Company presentation
Vicore Pharma Holding AB has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
Vicore Pharma Holding AB Transcript: Chardan's 10th Annual Healthcare Conference
ASPIRE is testing buloxibutid for 52 weeks, with results expected in summer 2027; management sees a sustained Phase II-A signal and expects Phase III to follow. The program targets epithelial repair and may suit combination therapy.
Vicore Pharma to Participate in the Chardan Healthcare Conference
STOCKHOLM, SE / ACCESS Newswire / October 13, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonist...
Vicore Pharma initiated with a Buy at Jefferies
Jefferies initiated coverage of Vicore Pharma (VCRE) with a Buy rating and $25 price target The firm views the company as a “high-risk/high-reward” idiopathic pulmonary fibrosis play. The share setup…
Increase in Number of Shares and Votes in Vicore Pharma
STOCKHOLM, SE / ACCESS Newswire / September 30, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agoni...
Vicore Pharma Holding AB Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
Recent advances in IPF therapy highlight the need for well-tolerated, effective drugs. Buloxibutid, an oral angiotensin II type 2 receptor agonist, showed unprecedented FVC improvement and strong tolerability in phase II-A, with a robust phase II-B trial underway and top-line data expected mid-2027.
Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum
STOCKHOLM, SE / ACCESS Newswire / September 17, 2026 / Vicore Pharma Holding AB (publ) (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of d...
Vicore Pharma Holding AB Slides: Company presentation
Vicore Pharma Holding AB has posted slides in relation to its latest quarterly earnings report, which was published on September 6, 2026.
Vicore Pharma to Participate in Upcoming Healthcare Conferences
STOCKHOLM, SE / ACCESS Newswire / September 1, 2026 / Vicore Pharma Holding AB (STO:VICO))(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, a...
Vicore Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference
STOCKHOLM, SE / ACCESS Newswire / August 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel clas...
Vicore Pharma Holding AB Slides: Company presentation
Vicore Pharma Holding AB has posted slides in relation to its latest quarterly earnings report, which was published on August 25, 2026.
Vicore Pharma to Present at the European Respiratory Society Congress 2026
STOCKHOLM, SE / ACCESS Newswire / August 24, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class o...
Vicore Pharma Holding AB Quarterly report: Q2 2026
Vicore Pharma Holding AB has published its Q2 2026 quarterly earnings report on August 21, 2026.
Vicore Pharma to Participate in the Leerink Therapeutics Forum
STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of d...